-
Lakartidningen
Topics: Candidiasis, Vulvovaginal; Condylomata Acuminata; Eczema; Female; Humans; Pruritus Vulvae; Vulva; Vulvar Diseases; Vulvar Lichen Sclerosus
PubMed: 20387759
DOI: No ID Found -
Zhonghua Fu Chan Ke Za Zhi Mar 2009To evaluate the etiology, clinicopathological characteristics, treatment and prognosis of VINIII.
OBJECTIVE
To evaluate the etiology, clinicopathological characteristics, treatment and prognosis of VINIII.
METHODS
Thirty-five patients with VINIII admitted in Cancer Hospital of Chinese Academy of Medical Sciences between 1993 and 2008 were analyzed retrospectively.
RESULTS
All 35 patients attended to hospital with the symptoms of pruritus vulvae and lumps. Among of them, there were 28 (80%) cases whose lesions presented as multiple plaques, while 7 (20%) cases lesion were monofocal. Fifteen out of 35 cases had coexistent with human papillomavirus (HPV) related lesions, and there were the evidence of HPV in 22 patients whose pathologic sections revealed koilocytes. 34 cases (97%) except one received different types of surgical resections, including wide local resection (14/34), simple vulvectomy (16/34) and simple vulvectomy plus perianal skin resection (4/34), while there two cases shown positive cut-edges and one of them received radiotherapy postoperatively. Four out of the 34 cases recurred locally in 2, 4, 6 and 22 months and received surgical treatment again or laser therapy, respectively. The median follow-up period was 66 months (range 1-166), and none of them were died of the disease itself except one case died of the concurrent cervical cancer. Among 26 cases received the investigation of the quality of life, there were nine cases (35%) suffered from sexual dysfunction after the operation, and one of them received vulvoplasty.
CONCLUSIONS
VINIII has good prognosis. The development of VINIII may be related to the infection of HPV, because most of them concurrent with HPV diseases. Its primary treatment is surgical resection, while affecting on the quality of life.
Topics: Adult; Aged; Biopsy; Carcinoma in Situ; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Papillomavirus Infections; Prognosis; Quality of Life; Retrospective Studies; Uterine Cervical Neoplasms; Vulva; Vulvar Neoplasms; Young Adult
PubMed: 19570437
DOI: No ID Found -
BJOG : An International Journal of... Sep 2009
Topics: Aged; Angina Pectoris; Female; Humans; Middle Aged; Nicorandil; Pain; Pruritus Vulvae; Ulcer; Vasodilator Agents; Vulvar Diseases; Vulvitis
PubMed: 19538410
DOI: 10.1111/j.1471-0528.2009.02260.x -
The Journal of Reproductive Medicine May 2009To identify objective clinical signs of vulvodynia and determine specific diagnostic tests for vulvodynia in women referred to a vulvar outpatient clinic for vulval...
OBJECTIVE
To identify objective clinical signs of vulvodynia and determine specific diagnostic tests for vulvodynia in women referred to a vulvar outpatient clinic for vulval complaints.
STUDY DESIGN
A retrospective study was performed of the medical records of 201 consecutive Danish patients suspected of suffering from vulvodynia who were referred to a vulvar outpatient clinic (Department of Gynecology, Rigshospitalet University Hospital) between October 2003 and January 2006.
RESULTS
Of 201 women, 117 were diagnosed with vulvodynia and 84 had other diagnoses. Of the women diagnosed with vulvodynia in the vulvar clinic, 88.9% were correctly diagnosed before referral. The women with vulvodynia were more likely to report dyspareunia (chi2 = 7.89, p = 0.005) and stinging pain (chi2 = 3.74, p = 0.05). The nonvulvodynia group was more likely to report a tendency toward fissures (chi2 = 5.94, p < 0.05).
CONCLUSION
Self-reported dyspareunia and stinging pain are strongly associated with vulvodynia. Self-reported pruritus and a tendency toward fissures are not likely to be associated with vulvodynia. Whether vulvar biopsies should be performed regularly when redness and pain is present must be explored further in prospective studies.
Topics: Adult; Candidiasis, Vulvovaginal; Condylomata Acuminata; Dyspareunia; Endometriosis; Female; Humans; Lichen Planus; Middle Aged; Neurodermatitis; Pain; Pruritus Vulvae; Retrospective Studies; Vaginosis, Bacterial; Vulvar Diseases; Vulvar Lichen Sclerosus
PubMed: 19517691
DOI: No ID Found -
European Journal of Dermatology : EJD 2009
Topics: Boric Acids; Child; Female; Humans; Pruritus Vulvae; Skin Diseases, Papulosquamous; Vulvar Diseases
PubMed: 19467973
DOI: 10.1684/ejd.2009.0697 -
International Journal of STD & AIDS May 2009A 24-year-old lady presented to an evening genitourinary (GU) clinic with a short history of vulval and anal irritation. On perianal examination, several threadworms...
A 24-year-old lady presented to an evening genitourinary (GU) clinic with a short history of vulval and anal irritation. On perianal examination, several threadworms were visible. Symptoms resolved with oral mebendazole and strict personal and environmental hygiene. Threadworm is a common and easily treatable cause of pruritus ani, yet is underreported in GU literature. If the history is suggestive, consider performing the diagnostic cellophane test and/or prescribing empirical treatment.
Topics: Adult; Animals; Antinematodal Agents; Enterobiasis; Enterobius; Female; Humans; Mebendazole; Pruritus Ani; Pruritus Vulvae
PubMed: 19386978
DOI: 10.1258/ijsa.2009.008507 -
JPMA. the Journal of the Pakistan... Mar 2009To assess knowledge among medical students of Ziauddin University regarding Diabetes Mellitus.
OBJECTIVE
To assess knowledge among medical students of Ziauddin University regarding Diabetes Mellitus.
METHODS
A cross sectional survey of medical students from first year to final year at the medical college was conducted on a pretested self-administered questionnaire. Students were divided into preclinical and clinical years for analysis.
RESULTS
A total of 366 students participated, with 145 (39.6%) from the preclinical group and 221 (60.4%) from the clinical group. Overall 89% students knew that diabetes is a metabolic disorder, 78% knew that pancreas is the site of insulin production and 77% students correctly identified main target organ of insulin. Regarding presentation, 67% said polyphagia, 50% said weight loss while only 18% claimed pruritus vulvae to be the presenting symptom. Majority from the clinical group (95%) while 86% of preclinical group knew about risk factors for diabetes (p = 0.003). Regarding prevention, 89% of clinical group knew that diabetes is preventable but 49% preclinical students did not have an idea of prevention (p < 0.001). A large number from clinical group (87%) said that there is some criteria of screening for diabetes while only 30% of preclinical group knew about screening (p < 0.001). Correct diagnostic criteria for diabetes according to WHO was identified by 55% clinical and only 6% of preclinical students (p < 0.001). Over two-third (78%) of clinical while only 50% of preclinical students said that diabetes should not always be treated with drugs (p < 0.001).
CONCLUSION
The knowledge of students about diabetes was more in the clinical group as compared to the preclinical group, whereas, overall knowledge of the students was adequate. Medical students are the future physicians, therefore the medical curriculum should lay emphasis on educating students, patient based clinically oriented approaches for dealing with this epidemiologically important disease.
Topics: Adult; Clinical Competence; Cross-Sectional Studies; Diabetes Mellitus; Education, Medical, Undergraduate; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Pakistan; Students, Medical; Surveys and Questionnaires
PubMed: 19288944
DOI: No ID Found -
The European Journal of General Practice 2009To determine the effectiveness of triamcinolone cream in the treatment of non-specific pruritus vulvae. (Randomized Controlled Trial)
Randomized Controlled Trial
OBJECTIVE
To determine the effectiveness of triamcinolone cream in the treatment of non-specific pruritus vulvae.
METHODS
A total of 50 patients, aged between 8 and 55 years, with non-specific pruritus vulvae were consecutively included in a double-blind randomized controlled trial by their general practitioner in 25 general practices in the Netherlands. Analysis was by "intention to treat". An infectious cause was excluded by a vaginal and cervical swab. After randomization, 27 patients were treated with triamcinolone cream and 23 patients with a placebo cream. The effectiveness was assessed by: change in the severity of itch visual analogue scale (VAS) score; the percentage of patients with complete recovery; and changes in general health according to COOP/WONCA charts.
RESULTS
The mean decrease in severity of itch was 2.08 points in the triamcinolone group compared to 3.26 points in the placebo group. Forty-two per cent of the women in the triamcinolone group completely recovered versus 35% in the placebo group. There was no difference in general health perception between the two groups. After 12 weeks, more than 80% in both groups reported recurrent vulval itch.
CONCLUSION
No significant differences in effectiveness were found between the two groups, because both treatments were ineffective. We can conclude that triamcinolone cream is therefore not the treatment of first choice for non-specific pruritus vulvae.
Topics: Administration, Topical; Adolescent; Adult; Double-Blind Method; Female; Glucocorticoids; Humans; Middle Aged; Netherlands; Pruritus Vulvae; Severity of Illness Index; Triamcinolone Acetonide; Young Adult
PubMed: 19169912
DOI: 10.1080/13814780802705976 -
The Journal of Dermatological Treatment 2008Pruritus vulvae may have a variety of causes, such as infections, dermatologic disorders or non-neoplastic/neoplastic vulvar diseases. (Clinical Trial)
Clinical Trial
BACKGROUND
Pruritus vulvae may have a variety of causes, such as infections, dermatologic disorders or non-neoplastic/neoplastic vulvar diseases.
OBJECTIVES
To investigate the efficacy and side effects of topical pimecrolimus 1% cream for pruritus vulvae.
METHODS
Twelve postmenopausal diabetic women with vulvar lichen simplex chronicus were enrolled in this trial. Each patient was treated with pimecrolimus 1% cream which was applied twice daily in a thin layer to the vulvae for 3 months. Clinical examination and recording of patients' symptoms using a scoring system was performed by the same physician before, after 4 weeks and after 3 months of therapy.
RESULTS
All of the patients completed the study. A substantial decrease in pruritus after treatment was reported by the patients at the 4th week (2.17+/-0.72, p<0.01) and 3rd month of treatment (0.42+/-0.92, p<0.001) when compared with the baseline score (3.75+/-0.45). Follow-up of the patients after 3 months of treatment showed that complete cure occurred in 10 patients (83.3%) and the pruritus was improved in two (16.7%) patients.
CONCLUSIONS
Pimecrolimus 1% cream seems to be an effective and safe treatment modality for pruritus in postmenopausal women with vulvar lichen simplex chronicus.
Topics: Adult; Aged; Dermatologic Agents; Diabetes Complications; Female; Humans; Middle Aged; Neurodermatitis; Postmenopause; Prospective Studies; Pruritus Vulvae; Tacrolimus
PubMed: 19160532
DOI: 10.1080/09546630801955341 -
The Australasian Journal of Dermatology Nov 2008We report the successful treatment of severe long-standing erosive vulvovaginal lichen planus in four adult female patients using 2.5-7.5 mg of oral methotrexate once...
We report the successful treatment of severe long-standing erosive vulvovaginal lichen planus in four adult female patients using 2.5-7.5 mg of oral methotrexate once weekly in conjunction with topical clobetasol dipropionate 0.05% ointment and tacrolimus 0.03-0.10% ointment. All cases experienced improvement in symptoms and healing of lesions within 4-8 weeks. Methotrexate was well tolerated and no adverse events have been observed in any of the patients at follow up 4-6 months later.
Topics: Adult; Anal Canal; Constriction, Pathologic; Dermatologic Agents; Female; Humans; Lichen Planus; Methotrexate; Middle Aged; Pruritus Vulvae; Treatment Outcome; Vaginal Diseases; Vulvar Diseases
PubMed: 18855784
DOI: 10.1111/j.1440-0960.2008.00472.x